Compare TBPH & THRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | THRM |
|---|---|---|
| Founded | 2013 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 993.7M | 1.1B |
| IPO Year | N/A | 1993 |
| Metric | TBPH | THRM |
|---|---|---|
| Price | $18.67 | $36.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $27.80 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 528.0K | 188.3K |
| Earning Date | 11-10-2025 | 10-23-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.58 | ★ 0.99 |
| Revenue | $80,327,000.00 | ★ $1,468,728,000.00 |
| Revenue This Year | $70.78 | $3.56 |
| Revenue Next Year | N/A | $2.52 |
| P/E Ratio | ★ $32.28 | $37.31 |
| Revenue Growth | ★ 27.12 | N/A |
| 52 Week Low | $7.90 | $22.75 |
| 52 Week High | $20.33 | $41.09 |
| Indicator | TBPH | THRM |
|---|---|---|
| Relative Strength Index (RSI) | 57.92 | 53.19 |
| Support Level | $17.25 | $36.70 |
| Resistance Level | $19.13 | $37.89 |
| Average True Range (ATR) | 0.65 | 0.99 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 78.72 | 50.34 |
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the United States, China, South Korea, Germany, Japan, the Czech Republic, and other countries.